Request Demo

Last update 23 Jan 2025

CD81

Last update 23 Jan 2025

Basic Info

Synonyms

26 kDa cell surface protein TAPA-1, CD81, CD81 antigen

+ [7]

Introduction

Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Essential for trafficking and compartmentalization of CD19 receptor on the surface of activated B cells (PubMed:20237408, PubMed:27881302, PubMed:16449649). Upon initial encounter with microbial pathogens, enables the assembly of CD19-CR2/CD21 and B cell receptor (BCR) complexes at signaling TERMs, lowering the threshold dose of antigen required to trigger B cell clonal expansion and antibody production (PubMed:15161911, PubMed:20237408). In T cells, facilitates the localization of CD247/CD3 zeta at antigen-induced synapses with B cells, providing for costimulation and polarization toward T helper type 2 phenotype (PubMed:22307619, PubMed:23858057, PubMed:8766544). Present in MHC class II compartments, may also play a role in antigen presentation (PubMed:8409388, PubMed:8766544). Can act both as positive and negative regulator of homotypic or heterotypic cell-cell fusion processes. Positively regulates sperm-egg fusion and may be involved in acrosome reaction (By similarity). In myoblasts, associates with CD9 and PTGFRN and inhibits myotube fusion during muscle regeneration (By similarity). In macrophages, associates with CD9 and beta-1 and beta-2 integrins, and prevents macrophage fusion into multinucleated giant cells specialized in ingesting complement-opsonized large particles (PubMed:12796480). Also prevents the fusion of mononuclear cell progenitors into osteoclasts in charge of bone resorption (By similarity). May regulate the compartmentalization of enzymatic activities. In T cells, defines the subcellular localization of dNTPase SAMHD1 and permits its degradation by the proteasome, thereby controlling intracellular dNTP levels (PubMed:28871089). Also involved in cell adhesion and motility. Positively regulates integrin-mediated adhesion of macrophages, particularly relevant for the inflammatory response in the lung (By similarity). (Microbial infection) Specifically required for Plasmodium falciparum infectivity of hepatocytes, controlling sporozoite entry into hepatocytes via the parasitophorous vacuole and subsequent parasite differentiation to exoerythrocytic forms. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes. Association with CLDN1 and the CLDN1-CD81 receptor complex is essential for HCV entry into host cell. (Microbial infection) Involved in SAMHD1-dependent restriction of HIV-1 replication. May support early replication of both R5- and X4-tropic HIV-1 viruses in T cells, likely via proteasome-dependent degradation of SAMHD1.

Drugs associated with CD81

CN118146394

Patent Mining

Target

CD81

Mechanism-

Active Org.

Hunan Huilin Life Technology Co., Ltd.

Originator Org.

Hunan Huilin Life Technology Co., Ltd.

Active Indication

Lymphoproliferative Disorders [+1]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with CD81

100 Translational Medicine associated with CD81

0 Patents (Medical) associated with CD81

2,337

Literatures (Medical) associated with CD81

01 Jun 2025·Comparative Biochemistry and Physiology Part D: Genomics and Proteomics

Comparative proteomic analysis reveals the response mechanism of freshwater leech (Whitmania pigra) under heat-stress challenge

Article

Author: Kaunda, Mange ; Liu, Bo ; Xiong, Liangwei ; Zheng, Xiaochuan ; Wang, Haihua ; Fu, Huiyun ; Wang, Quan ; Wang, Aimin ; Wang, Shuaibing

Temperature is an environmental parameter that remarkably affects the survival and organism health of poikilothermal animal-Whitmania pigra Whitman. Heat stress destroys the physiological homeostasis of intestine tissue. However, no studies on the intestinal mucosa response of leech exposure to heat stress have been reported so far. To identify the biomarker proteins involved in heat stress response, we performed a Tandem mass tag (TMT)-based comparative proteomic analysis on leech's intestine after exposing to 27 °C and 35 °C. The cumulative mortality in the 35 °C heat stress group increased on the third day after stress compared with the control group. Mean-while, intestinal malondialdehyde (MDA) content was significantly up-regulated whereas total antioxidant capacity (T-AOC) was significantly down-regulated. A total of 3935 proteins were identified through proteomic analysis. Heat stress resulted in 144 differential proteins; 75 were up-regulated, and 69 were down-regulated. The differential expression proteins in response to heat stress are mainly involved in calcium-binding proteins, molecular chaperones, cytoskeleton integrity, immune function and inflammation response, DNA damage and repair, ribosomal protein synthesis, stress hormones and neuro-transmitters, tumorigenesis, and apoptosis. Protein-protein network interaction analysis showed that HSP, CD8A, C3, CD63, CD81, MRPL58, MRPL15, HNRNPA1, AMBP, IGHEP1, SERPINC1, CYP3A4, ATP12A, RPS13, CaM, HSP70 binding protein, HSPA6, C4A, ANXA7, ARG1, ARG2, ATP1B, CALCA, HTR1B, and GNGT1 are the critical proteins of leeches resistance to heat stress. Our results systematically provide substantial responsive candidate proteins combating heat stress and enhance our understanding of the intrinsic response mechanisms of thermal sensitivities animal W. pigra facing heat exposure.

01 Mar 2025·European Journal of Obstetrics & Gynecology and Reproductive Biology

CD63 as a potential biomarker for patients with ovarian cancer

Article

Author: Masuyama, Hisashi ; Nakamura, Keiichiro ; Ida, Naoyuki ; Okamoto, Kazuhiro ; Hai Ly, Dao Thi ; Vu, Thuy Ha ; Hirasawa, Akira

INTRODUCTIONExosomes play an important role in regulating physiological processes and mediating the systemic dissemination of various types of cancer. We investigated the association of exosomal tetraspanins CD9, CD63, and CD81 in patients with ovarian cancer (OC).MATERIAL AND METHODSWe measured the plasma tetraspanins CD9, CD63, and CD81 by enzyme-linked immunosorbent assay in 91 patients who underwent treatment for OC between April 2018 and March 2024. Additionally, we analyzed clinical pathologic factors, chemotherapy response, and prognosis.RESULTSIn terms of stages, CD63 expression was significantly higher in patients with stage IV compared to those with stage I OC (p = 0.003). In terms of histological type, CD63 expression was significantly higher in high-grade serous carcinoma (HGSC) than in clear cell carcinoma (CCC) with OC (p = 0.009). Furthermore, CD63 levels were significantly higher in advanced-stage, HGSC than in patients with early-stage, non-HGSC and early-stage, HGSC OC (p = 0.045 and p = 0.002, respectively). In the Neoadjuvant chemotherapy (NAC) of 12 patients with OC assessed as having either a partial response (PR) or complete response (CR), CD63 was significantly decreased (p = 0.043), whereas perforin was significantly increased (p = 0.001). In the NAC of 16 patients with OC, CD63 of the response rate to chemotherapy tended to differ between the progressive disease (PD) and PR/CR groups (p = 0.056). A moderate inverse correlation was observed between CD63 and perforin levels (R = 0.638, R² = 0.428, p = 0.008).CONCLUSIONSCD63 could be a potential biomarker for all types of OC patients.

01 Mar 2025·Current Molecular Medicine

Exosomes Derived from Astragaloside IV-pretreated Endothelial Progenitor Cells (AS-IV-Exos) Alleviated Endothelial Oxidative Stress and Dysfunction via the miR-210/ Nox2/ROS Pathway

Article

Author: Zou, Xiao-Ling ; Huang, Zi-Xin ; Zhang, Xi ; Peng, Sai ; Zhao, Lan ; Xiong, Wu ; Liu, Xiang-Nan ; Lei, Hua-Juan

Background:Chronic hyperglycemia in diabetes induces oxidative stress, leading to damage to the vascular system. In this study, we aimed to evaluate the effects and mechanisms of AS-IV-Exos in alleviating endothelial oxidative stress and dysfunction caused by high glucose (HG).Methods:Histopathological changes were observed using HE staining, and CD31 expression was assessed through immunohistochemistry (IHC). Cell proliferation was evaluated through CCK8 and EDU assays. The levels of ROS, SOD, and GSH-Px in the skin tissues of each group were measured using ELISA. Cell adhesion, migration, and tube formation abilities were assessed using adhesion, Transwell, and tube formation experiments. ROS levels in HUVEC cells were measured using flow cytometry. The levels of miR-210 and Nox2 were determined through quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The expression of Nox2, SOD, GSH-Px, CD63, and CD81 was confirmed using WB.Results:The level of miR-210 was reduced in diabetes-induced skin damage, while the levels of Nox2 and ROS increased. Treatment with AS-IV increased the level of miR-210 in EPC-Exos. Compared to Exos, AS-IV-Exos significantly reduced the proliferation rate, adhesion number, migration speed, and tube-forming ability of HGdamaged HUVEC cells. AS-IV-Exos also significantly decreased the levels of SOD and GSH-Px in HG-treated HUVEC cells and reduced the levels of Nox2 and GSH-Px. However, ROS levels and Nox2 could reverse this effect.Conclusion:AS-IV-Exos effectively alleviated endothelial oxidative stress and dysfunction induced by HG through the miR-210/Nox2/ROS pathway.

News (Medical) associated with CD81

11 May 2021

·www.globenewswire.com

Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG

Los Angeles, USA, May 10, 2021 (GLOBE NEWSWIRE) -- Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor. DelveInsight’s “Anti-CD19 Antibody Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Anti-CD19 Antibody pipeline landscapes. It comprises Anti-CD19 Antibody pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Anti-CD19 Antibody therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Anti-CD19 Antibody pipeline products. Some of the key takeaways of the Anti-CD19 Antibody Pipeline Report Get an overview of pipeline landscape @ Anti-CD19 Antibody Clinical Trials Analysis Anti-CD19 Antibody, a cluster of differentiation 19 (CD19), is a cell surface molecule expressed on B- lineage cells and follicular dendritic cells. CD19 comprises two extracellular immunoglobulin-like domains and an extensive cytoplasmic tail. It functions as a positive regulator of B-cell receptor signalling in conjunction with CD21 and CD81. CD19 is expressed throughout B-cell development and plays a critical role in maintaining the balance between humoral, antigen-induced immune response and tolerance induction. Anti-CD19 Antibody Emerging Drugs Inebilizumab is a humanised monoclonal antibody designed to target and deplete CD19-expressing B cells through antibody-dependent cell-mediated cytotoxicity. Research and DevelopmentMyasthenia GravisPhase III NCT04524273: In August 2020, Viela Bio initiated a randomised, double-blind, multicenter, placebo-controlled Phase 3 study with an open-label period to assess the efficacy and safety of Inebilizumab in adults with Myasthenia Gravis. This study is a phase 3, randomised, double-blind, placebo-controlled study conducted at approximately 100 study sites. About 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. The study is estimated to get completed by December 2024 with 252 registered participants. IgG4-Related Disease Phase IIINCT04540497: In October 2020, Viela Bio initiated a Phase 3, randomised, double-blind, multicenter, and placebo-controlled study of Inebilizumab efficacy and safety in IgG4-Related Disease. This study focuses on defining the effectiveness and safety of Inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD). The study is estimated to get completed by June 2024 with 160 enrolled participants. For further information, refer to the detailed report @ Anti-CD19 Antibody Pipeline Therapeutics Scope of Anti-CD19 Antibody Pipeline Drug Insight Key Questions regarding Current Anti-CD19 Antibody Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Anti-CD19 Antibody Drugs Pipeline Report Related Reports DelveInsight's Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight’s Global Kinase Inhibitor Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Alzheimer's disease Market Insights, Epidemiology and Market Forecast 2030 report provides an overview of disease and understanding of historical and forecasted epidemiology. DelveInsight's Anemia in CKD patients - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's ATCL Market report 2030 delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market trends in 7MM. Hidradenitis Suppurativa Market Research Report presents a detailed analysis of HS Epidemiology, Drug therapies, and pipeline for the study period from 2017-2030. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Portfolio Management Services to understand the competencies, leverage strengths to prioritise strategic goals and understand the market’s current needs.

CollaborateAntibodyADC

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis